Want to see ENSC full AI Analyst Report?
Top Page
Ensysce Biosciences
(NASDAQ:ENSC)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.46
▲(15.25% Upside)
Action:Reiterated
Date:10/13/26
The score is primarily held down by weak financial performance (large losses, sustained cash burn, and negative equity). Technicals are a partial offset with a bullish trend, but overbought signals increase near-term volatility risk. Corporate events are mixed—pipeline/financing progress is tempered by Nasdaq compliance and listing-process uncertainty, while valuation remains difficult to support due to negative earnings and no dividend.
Positive Factors
Pipeline Expansion
The Cy Biopharma acquisition broadens Ensysce beyond its opioid technology base by adding CY-200, an orphan-designated therapy for complex regional pain syndrome. A wider pain-focused pipeline can diversify development opportunities and create additional clinical catalysts over the next several quarters.
Negative Factors
Persistent Losses
The company remains far from operating profitability, with losses many times larger than its limited revenue base. This indicates that development and corporate costs currently exceed commercial income by a wide margin, making earnings improvement dependent on successful clinical progress and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Expansion
The Cy Biopharma acquisition broadens Ensysce beyond its opioid technology base by adding CY-200, an orphan-designated therapy for complex regional pain syndrome. A wider pain-focused pipeline can diversify development opportunities and create additional clinical catalysts over the next several quarters.
Read all positive factors
Ensysce Biosciences (ENSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.15M
Dividend YieldN/A
Average Volume (3M)506.16K
Price to Earnings (P/E)―
Beta (1Y)2.46
Revenue Growth-39.29%
EPS Growth27.41%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.76
Shares Outstanding19,456,795
10 Day Avg. Volume520,710
30 Day Avg. Volume506,162
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit2.55
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$2.00Price Target Upside400.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$4.60M
Ensysce Biosciences Business Overview & Revenue Model
Company Description
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and over...
How the Company Makes Money
Ensysce Biosciences is a clinical-stage company and does not have publicly established, recurring product sales in the way commercial-stage pharmaceutical companies do; as a result, any routine revenue from marketed drugs is not available. The com...
Ensysce Biosciences Earnings Call Summary
Earnings Call Date:Mar 15, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant clinical achievements, including FDA breakthrough designations and successful trial completions, against a backdrop of financial challenges and reduced funding. The company is making progress toward its goals but needs additional funding to maintain momentum.Positive Updates
Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
Negative Updates
Limited Cash Reserves
The company ended 2023 with $1.1 million in cash and cash equivalents, highlighting the need for additional funding to initiate Phase III trials.
Read all updates
Q4-2023 Updates
Positive
Negative
Significant Clinical Progress
2023 marked a year of exceptional clinical progress for Ensysce's next-generation analgesics, moving programs closer to commercialization.
Read all positive updates
Company Guidance
During Ensysce Biosciences' Q4 2023 earnings call, the company provided detailed guidance on its advancements and future plans. Ensysce reported significant clinical progress with its next-generation opioid analgesics, focusing on the PF614 and PF614-MPAR products. The company completed five clinical trials for PF614, including a human abuse potential study and an analgesic efficacy study. Ensysce plans to initiate Phase III trials for PF614 in the second half of 2024, following FDA feedback. They also received breakthrough therapy designation for PF614-MPAR, highlighting its potential to prevent opioid overdose. Financially, Ensysce ended 2023 with $1.1 million in cash, supplemented by early 2024 warrant exercises and plans to raise additional funds before starting Phase III trials. The company’s R&D expenses decreased in 2023, totaling $7.6 million, with a focus on optimizing manufacturing and preparing for pivotal clinical trials.Ensysce Biosciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.61M | -10.15M | -6.70M | -10.27M | -24.10M | -27.85M |
| Net Income | -12.62M | -10.18M | -7.99M | -10.61M | -24.17M | -29.08M |
Balance Sheet | ||||||
| Total Assets | 2.96M | 7.45M | 5.60M | 2.71M | 5.89M | 16.42M |
| Cash, Cash Equivalents and Short-Term Investments | 676.70K | 4.31M | 3.50M | 1.12M | 3.15M | 12.26M |
| Total Debt | 196.84K | 306.71K | 301.66K | 854.70K | 4.43M | 17.21M |
| Total Liabilities | 4.07M | 4.57M | 2.22M | 3.36M | 9.91M | 24.58M |
| Stockholders Equity | -781.70K | 3.21M | 3.71M | -322.86K | -3.71M | -7.88M |
Cash Flow | ||||||
| Free Cash Flow | -8.98M | -7.93M | -7.50M | -10.78M | -17.89M | -8.24M |
| Operating Cash Flow | -8.86M | -7.81M | -7.50M | -10.78M | -17.89M | -8.24M |
| Investing Cash Flow | -123.64K | -123.64K | 0.00 | 0.00 | 4.50K | 0.00 |
| Financing Cash Flow | 7.44M | 8.74M | 9.88M | 8.76M | 8.77M | 20.31M |
Ensysce Biosciences Technical Analysis
Neutral
0.40
Price Trends
0.45
Positive
0.37
Positive
0.45
Positive
Market Momentum
0.02
Positive
48.37
Neutral
15.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENSC, the sentiment is Neutral. The current price of 0.4 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 0.45, and below the 200-day MA of 0.45, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 48.37 is Neutral, neither overbought nor oversold. The STOCH value of 15.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENSC.
Ensysce Biosciences Risk Analysis
Ensysce Biosciences disclosed 48 risk factors in its most recent earnings report. Ensysce Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ensysce Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
ENSC
Ensysce Biosciences
0.45
-1.69
-78.97%
SILO
Silo Pharma
1.16
-7.38
-86.42%
ALZN
Alzamend Neuro
1.14
-1.31
-53.47%
Ensysce Biosciences Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Ensysce Biosciences Updates Series C Preferred Stock Terms
Neutral
Sep 29, 2026
On August 5, 2026, Ensysce Biosciences filed a Certificate of Designation for its Series C Non-Voting Convertible Preferred Stock with Delaware authorities, followed by a Certificate of Correction on August 6, 2026. These actions established key p...
Delistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
Ensysce Biosciences Gains Nasdaq Equity Compliance, Faces New Listing Hurdles
Negative
Aug 25, 2026
On May 21, 2026, Ensysce Biosciences disclosed that Nasdaq had warned the company over non-compliance with the $2.5 million stockholders’ equity requirement as of March 31, 2026, triggering a potential delisting process unless a remediation ...
Delistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period
Positive
Aug 24, 2026
On August 5, 2026, Ensysce Biosciences acquired Cy Biopharma, Inc. and entered into a Securities Purchase Agreement to issue 120,260 shares of Series C Preferred Stock for approximately $43 million in financing, structured in two tranches. At the ...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and Financing
Ensysce Acquires Cy Biopharma, Expands Pain Therapy Portfolio
Positive
Aug 6, 2026
On August 5, 2026, Ensysce Biosciences completed the stock-for-stock acquisition of Cy Biopharma, making Cy a wholly owned subsidiary and shifting majority ownership of the combined company to Cy’s former equityholders once Series C preferre...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.